| Literature DB >> 30609890 |
Serena Fortunato1, Chiara Lenzi1, Carlotta Granchi1, Valentina Citi1, Alma Martelli1, Vincenzo Calderone1, Sebastiano Di Pietro1, Giovanni Signore2, Valeria Di Bussolo3, Filippo Minutolo1.
Abstract
H2S donors are currently emerging as promising therapeutic agents in a wide variety of pathologies, including tumors. Cancer cells are characterized by an enhanced uptake of sugars, such as glucose. Therefore, novel glycoconjugated H2S donors were synthesized so that high concentrations of H2S can be selectively achieved therein. Dithiolethione portions or isothiocyanate portions were selected for their well-known H2S-releasing properties in the presence of biological substrates. A synthetic procedure employing trichloroacetimidate glycosyl donors was applied to produce, in a stereoselective fashion, C1-glycoconjugates, whereas C6-glycoconjugates were obtained by a Mitsunobu-based transformation. The resulting molecules were then tested for their anticancer effects on human pancreas adenocarcinoma ascites metastasis cell line AsPC-1. The most potent inhibitors of cell viability (6aβ and 7b) proved to release H2S inside the AsPC-1 cells and to alter the basal cell cycle.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30609890 DOI: 10.1021/acs.bioconjchem.8b00808
Source DB: PubMed Journal: Bioconjug Chem ISSN: 1043-1802 Impact factor: 4.774